ARTICLE | Tools & Techniques
-Omics overdrive
G3 uses six kinds of -omics and more to find targets
February 11, 2016 8:00 AM UTC
Over the past five years, Global Genomics Group LLC (G3) has been steadily amassing and analyzing pan-omics data from 7,500 individuals for the identification and validation of biomarkers and therapeutic targets. Now, the company has validated its system in coronary artery disease, signed up Sanofi as its first pharma partner, and is on the hunt for more.
The deal was announced on Jan. 5, three days before G3 and its collaborator GNS Healthcare Inc. disclosed results from their GLOBAL clinical study, which was designed to identify biomarkers and targets associated with coronary artery disease (CAD). ...